Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients

Phase 3

Completed

• Conditions: Pediatric Glaucoma; Elevated IOP in Pediatric Patients; Ocular Hypertension in Pediatric Patients
• Interventions: Drug: Timolol, 0.5% or 0.25% ophthalmic solution; Drug: Travoprost 0.004% PQ ophthalmic solution; Drug: Travoprost Vehicle

• Registration Number: NCT01652664
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this study is to evaluate the intraocular pressure (IOP)-lowering efficacy of Travoprost 0.004% POLYQUAD (PQ) ophthalmic solution compared to Timolol ophthalmic solution (0.5% or 0.25%) in pediatric glaucoma patients.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study First Submitted: 2012-07-26
• Study First Submitted QC: 2012-07-27
• Study First Posted: 2012-07-30
• Study Start: 2012-09
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Results First Submitted: 2015-03-31
• Results First Submitted QC: 2015-03-31
• Results First Posted: 2015-04-13
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-30
• Last Update Posted: 2015-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 184

Inclusion Criteria

• Diagnosis of pediatric glaucoma or ocular hypertension.
• Qualifying mean IOP at the Eligibility Visit in at least one eye.
• Written informed consent, including assent when applicable, MUST be obtained from the parent or legally authorized representative prior to any procedure specified in the protocol, including screening procedures.
• Other protocol-defined inclusion criteria may apply.

Read More

Exclusion Criteria

• Females of childbearing potential who are pregnant, intend to become pregnant during the study period, breast feeding, or not using any form of birth control measures.
• History of chronic, recurrent or severe inflammatory eye disease.
• Ocular trauma requiring medical attention within the past 3 months prior to the Screening Visit.
• Ocular infection or ocular inflammation within the past 30 days prior to the Screening Visit.
• Clinically significant or progressive retinal disease.
• Severe ocular pathology (including severe dry eye) that, in the opinion of the Investigator, would preclude the administration of a topical prostaglandin analog or a topical beta-blocker.
• Intraocular surgery in the study eye within 30 days prior to the Screening Visit.
• Any abnormality preventing reliable applanation tonometry.
• Other protocol-defined exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Timolol	Timolol, 0.5% or 0.25% ophthalmic solution	Timolol, 0.5% or 0.25% ophthalmic solution, 1 drop administered in each eye twice daily (once in the morning and once in the evening) for 3 months
Travoprost	Travoprost 0.004% PQ ophthalmic solution	Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months
Travoprost	Travoprost Vehicle	Travoprost 0.004% PQ ophthalmic solution, 1 drop administered in each eye in the evening with travoprost vehicle administered once daily in the morning for 3 months

Primary Outcome Measures

Name	Time	Method
Mean Change From Baseline in IOP at Month 3	Baseline (Day 0), Month 3	IOP (fluid pressure inside the eye) was assessed using a calibrated tonometer and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye from each participant was chosen as the study eye and only the study eye was used for analysis.